In pancreatic cancer, ubiquitin-specific protease 8 (USP8) catalyzes the deubiquitination of PD-L1 by inhibiting ubiquitin-regulated proteasome degradation, the combined therapy of USP8 inhibitors with anti-PD-L1 effectively inhibits pancreatic tumor growth by activating cytotoxic T cells [295]. This evidence concerns the gene USP8 and pancreatic neoplasm.